Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Nurse-led vs. usual-care for atrial fibrillation.

Wijtvliet EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, Rienstra M, Folkeringa RJ, Bronzwaer P, Elvan A, Elders J, Tukkie R, Luermans JGLM, Van Asselt ADIT, Van Kuijk SMJ, Tijssen JG, Crijns HJGM.

Eur Heart J. 2019 Sep 23. pii: ehz666. doi: 10.1093/eurheartj/ehz666. [Epub ahead of print]

PMID:
31544925
2.

Diagnostic Accuracy of Computed Tomography to Exclude Pheochromocytoma: A Systematic Review, Meta-analysis, and Cost Analysis.

Buitenwerf E, Berends AMA, van Asselt ADI, Korteweg T, Greuter MJW, Veeger NJM, Links TP, Dullaart RPF, Kerstens MN.

Mayo Clin Proc. 2019 Oct;94(10):2040-2052. doi: 10.1016/j.mayocp.2019.03.030. Epub 2019 Sep 9.

PMID:
31515105
3.

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.

van Schoonhoven AV, Gout-Zwart JJ, de Vries MJS, van Asselt ADI, Dvortsin E, Vemer P, van Boven JFM, Postma MJ.

PLoS One. 2019 Sep 6;14(9):e0221856. doi: 10.1371/journal.pone.0221856. eCollection 2019.

4.

Personal and Societal Impact of Low Back Pain: The Groningen Spine Cohort.

Dutmer AL, Preuper HRS, Soer R, Brouwer S, B├╝ltmann U, Dijkstra PU, Coppes MH, Stegeman P, Buskens E, van Asselt ADI, Wolff AP, Reneman MF.

Spine (Phila Pa 1976). 2019 Jul 31. doi: 10.1097/BRS.0000000000003174. [Epub ahead of print]

PMID:
31369481
5.

Valuing Health Status in the First Year of Life: The Infant Health-Related Quality of Life Instrument.

Jabrayilov R, Vermeulen KM, Detzel P, Dainelli L, van Asselt ADI, Krabbe PFM.

Value Health. 2019 Jun;22(6):721-727. doi: 10.1016/j.jval.2018.12.009. Epub 2019 May 17.

6.

Patient-Centered Item Selection for a New Preference-Based Generic Health Status Instrument: CS-Base.

Krabbe PFM, van Asselt ADI, Selivanova A, Jabrayilov R, Vermeulen KM.

Value Health. 2019 Apr;22(4):467-473. doi: 10.1016/j.jval.2018.12.006. Epub 2019 Mar 14.

7.

Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D.

Arifin B, Idrus LR, van Asselt ADI, Purba FD, Perwitasari DA, Thobari JA, Cao Q, Krabbe PFM, Postma MJ.

Qual Life Res. 2019 May;28(5):1179-1190. doi: 10.1007/s11136-019-02105-z. Epub 2019 Jan 16.

8.

Group schema-focused therapy enriched with psychomotor therapy versus treatment as usual for older adults with cluster B and/or C personality disorders: a randomized trial.

van Dijk SDM, Veenstra MS, Bouman R, Peekel J, Veenstra DH, van Dalen PJ, van Asselt ADI, Boshuisen ML, van Alphen SPJ, van den Brink RHS, Oude Voshaar RC.

BMC Psychiatry. 2019 Jan 15;19(1):26. doi: 10.1186/s12888-018-2004-4.

9.

Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment.

van Schoonhoven AV, van Asselt ADI, Tomaszewski M, Patel P, Khunti K, Gupta P, Postma MJ.

Hypertension. 2018 Nov;72(5):1117-1124. doi: 10.1161/HYPERTENSIONAHA.118.11227.

PMID:
30354817
10.

Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review.

Fitria N, van Asselt ADI, Postma MJ.

Eur J Health Econ. 2019 Apr;20(3):407-417. doi: 10.1007/s10198-018-1006-y. Epub 2018 Sep 18.

11.

Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda.

Zakiyah N, van Asselt ADI, Setiawan D, Cao Q, Roijmans F, Postma MJ.

Appl Health Econ Health Policy. 2019 Feb;17(1):65-76. doi: 10.1007/s40258-018-0430-6.

PMID:
30178267
12.

A descriptive system for the Infant health-related Quality of life Instrument (IQI): Measuring health with a mobile app.

Jabrayilov R, van Asselt ADI, Vermeulen KM, Volger S, Detzel P, Dainelli L, Krabbe PFM; Pediatrics expert group.

PLoS One. 2018 Aug 31;13(8):e0203276. doi: 10.1371/journal.pone.0203276. eCollection 2018.

13.

Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.

Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):991-999. doi: 10.5588/ijtld.17.0523.

PMID:
30092863
14.

Integrated and Person-Centered Care for Community-Living Older Adults: A Cost-Effectiveness Study.

Uittenbroek RJ, van Asselt ADI, Spoorenberg SLW, Kremer HPH, Wynia K, Reijneveld SA.

Health Serv Res. 2018 Oct;53(5):3471-3494. doi: 10.1111/1475-6773.12853. Epub 2018 Mar 24.

15.

Health-Related Quality of Life of Patients with HPV-Related Cancers in Indonesia.

Setiawan D, Dusafitri A, Galistiani GF, van Asselt ADI, Postma MJ.

Value Health Reg Issues. 2018 May;15:63-69. doi: 10.1016/j.vhri.2017.07.010. Epub 2017 Sep 3.

PMID:
29474181
16.

Study protocol for a randomised controlled multicentre study: the Foraminotomy ACDF Cost-Effectiveness Trial (FACET) in patients with cervical radiculopathy.

Broekema AE, Kuijlen JM, Lesman-Leegte GA, Bartels RH, van Asselt AD, Vroomen PC, van Dijk JM, Reneman MF, Soer R, Groen RJ; FACET study group investigators.

BMJ Open. 2017 Jan 5;7(1):e012829. doi: 10.1136/bmjopen-2016-012829.

17.

Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review.

Zakiyah N, van Asselt AD, Roijmans F, Postma MJ.

PLoS One. 2016 Dec 19;11(12):e0168447. doi: 10.1371/journal.pone.0168447. eCollection 2016. Review.

18.

Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.

van Heesch MM, van Asselt AD, Evers JL, van der Hoeven MA, Dumoulin JC, van Beijsterveldt CE, Bonsel GJ, Dykgraaf RH, van Goudoever JB, Koopman-Esseboom C, Nelen WL, Steiner K, Tamminga P, Tonch N, Torrance HL, Dirksen CD.

Hum Reprod. 2016 Nov;31(11):2527-2540. Epub 2016 Oct 6.

PMID:
27907897
19.

Identifying and prioritizing lower value services from Dutch specialist guidelines and a comparison with the UK do-not-do list.

Wammes JJ, van den Akker-van Marle ME, Verkerk EW, van Dulmen SA, Westert GP, van Asselt AD, Kool RB.

BMC Med. 2016 Nov 25;14(1):196.

20.

Cost-effectiveness of supervised exercise therapy compared with endovascular revascularization for intermittent claudication.

van den Houten MM, Lauret GJ, Fakhry F, Fokkenrood HJ, van Asselt AD, Hunink MG, Teijink JA.

Br J Surg. 2016 Nov;103(12):1616-1625. doi: 10.1002/bjs.10247. Epub 2016 Aug 11.

PMID:
27513296
21.

Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis.

Zakiyah N, van Asselt AD, Postma MJ.

J Med Econ. 2017 Mar;20(3):280-287. doi: 10.1080/13696998.2016.1254090. Epub 2016 Nov 11.

PMID:
27786570
22.
23.

An Online Health Prevention Intervention for Youth with Addicted or Mentally Ill Parents: Experiences and Perspectives of Participants and Providers from a Randomized Controlled Trial.

Woolderink M, Bindels JA, Evers SM, Paulus AT, van Asselt AD, van Schayck OC.

J Med Internet Res. 2015 Dec 2;17(12):e274. doi: 10.2196/jmir.4817.

24.

Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments.

Zakiyah N, Postma MJ, Baker PN, van Asselt AD; IMPROvED Consortium.

Pharmacoeconomics. 2015 Oct;33(10):1069-82. doi: 10.1007/s40273-015-0291-x. Review.

25.

Methodological considerations in service use assessment for children and youth with mental health conditions; issues for economic evaluation.

Woolderink M, Lynch FL, van Asselt AD, Beecham J, Evers SM, Paulus AT, van Schayck CP.

Adm Policy Ment Health. 2015 May;42(3):296-308. doi: 10.1007/s10488-014-0570-4.

PMID:
24961357
26.

Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).

Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators.

JACC Heart Fail. 2013 Feb;1(1):64-71. doi: 10.1016/j.jchf.2012.08.002. Epub 2013 Feb 4.

27.

[E-research: problems with anonymity and consent].

Woolderink M, van Asselt AD, van Schayck CP, van Wijmen FC.

Ned Tijdschr Geneeskd. 2013;157(51):A6828. Dutch.

PMID:
24345359
28.

The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non-ST-elevation myocardial infarction patients: design and rationale of the CARdiovascular Magnetic rEsoNance imaging and computed Tomography Angiography (CARMENTA) trial.

Smulders MW, Kietselaer BL, Das M, Wildberger JE, Crijns HJ, Veenstra LF, Brunner-La Rocca HP, van Dieijen-Visser MP, Mingels AM, Dagnelie PC, Post MJ, Gorgels AP, van Asselt AD, Vogel G, Schalla S, Kim RJ, Bekkers SC.

Am Heart J. 2013 Dec;166(6):968-75. doi: 10.1016/j.ahj.2013.09.012. Epub 2013 Oct 23.

29.

Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study.

Boyne JJ, Van Asselt AD, Gorgels AP, Steuten LM, De Weerd G, Kragten J, Vrijhoef HJ.

J Telemed Telecare. 2013 Jul;19(5):242-8. doi: 10.1177/1357633X13495478. Epub 2013 Jul 9.

PMID:
24163233
30.

Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

Ramos GF, van Asselt AD, Kuiper S, Severens JL, Maas T, Dompeling E, Knottnerus JA, van Schayck OC.

Eur J Health Econ. 2014 Nov;15(8):869-83. doi: 10.1007/s10198-013-0532-x. Epub 2013 Oct 6.

PMID:
24096902
31.

Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis.

Deshpande SN, van Asselt AD, Tomini F, Armstrong N, Allen A, Noake C, Khan K, Severens JL, Kleijnen J, Westwood ME.

Health Technol Assess. 2013 Sep;17(40):1-138. doi: 10.3310/hta17400. Review.

32.

Cost-effectiveness analysis of sacral neuromodulation for faecal incontinence in The Netherlands.

van Wunnik BP, Visschers RG, van Asselt AD, Baeten CG.

Colorectal Dis. 2012 Dec;14(12):e807-14. doi: 10.1111/codi.12002.

PMID:
22943485
33.

Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.

Ramos GF, Kuiper S, Dompeling E, van Asselt AD, de Grauw WJ, Knottnerus JA, van Schayck OC, Schermer TR, Severens JL.

BMC Med Res Methodol. 2011 Nov 9;11:150. doi: 10.1186/1471-2288-11-150.

34.

Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice.

van Asselt AD, Nicolaï SP, Joore MA, Prins MH, Teijink JA; Exercise Therapy in Peripheral Arterial Disease Study Group.

Eur J Vasc Endovasc Surg. 2011 Jan;41(1):97-103. doi: 10.1016/j.ejvs.2010.06.024. Epub 2010 Dec 14.

35.

How to deal with cost differences at baseline.

van Asselt AD, van Mastrigt GA, Dirksen CD, Arntz A, Severens JL, Kessels AG.

Pharmacoeconomics. 2009;27(6):519-28. doi: 10.2165/00019053-200927060-00007.

PMID:
19640014
36.

Surgical site infections: how high are the costs?

Broex EC, van Asselt AD, Bruggeman CA, van Tiel FH.

J Hosp Infect. 2009 Jul;72(3):193-201. doi: 10.1016/j.jhin.2009.03.020. Epub 2009 May 31. Review.

PMID:
19482375
37.

The EQ-5D: A useful quality of life measure in borderline personality disorder?

van Asselt AD, Dirksen CD, Arntz A, Giesen-Bloo JH, Severens JL.

Eur Psychiatry. 2009 Mar;24(2):79-85. doi: 10.1016/j.eurpsy.2008.11.001. Epub 2008 Dec 17.

PMID:
19095421
38.

Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy.

van Asselt AD, Dirksen CD, Arntz A, Giesen-Bloo JH, van Dyck R, Spinhoven P, van Tilburg W, Kremers IP, Nadort M, Severens JL.

Br J Psychiatry. 2008 Jun;192(6):450-7. doi: 10.1192/bjp.bp.106.033597.

PMID:
18515897
39.

Difficulties in calculating productivity costs: work disability associated with borderline personality disorder.

van Asselt AD, Dirksen CD, Arntz A, Severens JL.

Value Health. 2008 Jul-Aug;11(4):637-44. doi: 10.1111/j.1524-4733.2007.00288.x. Epub 2007 Dec 17.

40.

The cost of borderline personality disorder: societal cost of illness in BPD-patients.

van Asselt AD, Dirksen CD, Arntz A, Severens JL.

Eur Psychiatry. 2007 Sep;22(6):354-61. Epub 2007 Jun 4.

PMID:
17544636
41.

Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.

Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL.

Pharmacogenet Genomics. 2007 May;17(5):359-68.

PMID:
17429318

Supplemental Content

Loading ...
Support Center